Abstract
BACKGROUND
In a phase 1–2 trial, teclistamab, a bispecific antibody targeting CD3 on T-cell surfaces and B-cell maturation antigen on myeloma cells, showed durable responses in heavily pretreated patients with relapsed or refractory multiple myeloma. Daratumumab, a monoclonal antibody...
@Jonathan Edwards
Do you have any idea why IGG levels didn’t decrease after the three additional Daratumumab shots (please see post 406 above).
I think this paper is saying that IGG doesn’t decrease after a certain point.
https://pmc.ncbi.nlm.nih.gov/articles/PMC7271608/
If that is the case...
For the seven shot cohort, IGG didn’t decrease with the 3 additional shots (the yellow arrows). Any ideas about this? Maybe Daratumumab can’t deplete any more cells without NK cells?
I think the article could have been shortened by half or two thirds.
Wish there had been more discussion about Encephalitis lethargica, which may be a disease closely related to ME/CFS.
Also does anyone really need 50 years of psychoanalysis? Maybe the psychiatrist could have pulled the plug...
Autoimmune rheumatic diseases (AIRDs), such as rheumatoid arthritis and systemic lupus erythematosus, substantially affect quality of life, with viral infections increasingly recognized as potential but underappreciated triggers of worsening preexisting AIRD symptoms. Despite growing evidence...
Are we sure that Fluge specifically called out GPCR antibodies?
@Jonathan Edwards has been skeptical of the German antibody claims. IIRC, his argument was that if these antibodies were a factor they would need to be much much higher than normal levels, and they weren’t.
Try it now—should have been a gift link.
It’s about using “preventative” MRIs to catch early stage diseases/cancers. But insurance won’t pay for it.
It’s a bit hard to summarize because there is a tongue in cheek element to the writing—which makes it a mostly fun read.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.